World Biosimilars Market Potential Examined in New Report Published at MarketPublishers.com07 Feb 2012 • by Natalie Aster
LONDON – Notwithstanding some predictions of a muted or near nonexistent market for advanced biosimilars, a host of companies are positioning themselves for market entry. The move may reflect a growing confidence that as regulatory provision for biosimilars increases, and as the pipeline of prospective products matures, then the prospect of actually being able to launch products grows more realistic.
New market research report “Global Biosimilars: A Return to Optimism?” elaborated by Espicom Business Intelligence provides true and unprejudiced insights into the global biosimilars market environment, current and future products and the companies involved.
complete examination of the regulatory situation in the US, Europe and emerging markets;
detailed assessment of current biosimilar products and developers with market share by product – EPO, G-CSF, HGH, Human Insulin, Interferon (alfa & beta);
identification and analysis of likely second wave of advanced biologics to come to the market – Adalimumab, Etanercept, Infliximab, Rituximab, Trastuzumab;
overview of operational issues that will affect the adoption of biosimilars including pricing/reimbursement, clinician attitudes and patient acceptance;
position, activity, products, pipeline and plans of 50 leading players in the field.
Global Biosimilars: A Return to Optimism?
Published: January, 2012
Price: US$ 2.265,00
More new market research reports by the publisher can be found at Espicom Business Intelligence page.